parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.06 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in corticotrophs	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	7 Parkinson's trials, 0 stopped	1.00
literature PubMed	24 Parkinson's papers of 4,596	0.58
pathways Reactome	7 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 4159

receipt 4166: DCC in dopamine neurons, braak

power: full sample +0.27 (p 0.281, n 18), 95% CI -0.23 to +0.65. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.27 (p 0.281, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.29 (p 0.246, n 18). could be the mix.
skeptic: leave-one-out range +0.16 to +0.41, sign flips 0; without severely affected donors +0.27 (p 0.281, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for DCC in dopamine neurons.

case closed: nothing better to follow up.

receipt 4165: DCC in oligodendrocytes, braak

power: full sample -0.08 (p 0.748, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.05 (p 0.840, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.14 (p 0.573, n 18). could be the mix.
skeptic: leave-one-out range -0.19 to +0.06, sign flips 3; without severely affected donors -0.08 (p 0.748, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for DCC in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts